NCT07055568尚未招募不适用
A Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Allogeneic iNKT Cell Infusion in Subjects With Advanced Pancreatic Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine0 个研究点目标入组 18 人开始时间: 2025年9月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 18
- 主要终点
- Dose-limiting toxicity (DLT)
研究概览
简要总结
To evaluate the preliminary safety and tolerability of iNKT cell injection after infusion in each group of subjects, and to determine the maximum tolerated dose (MTD) and/or the recommended dose for extended studies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily participate in clinical research; Fully understand this study and voluntarily sign the informed consent form; Willing to follow and capable of completing all the test procedures;
- •Male or female, aged 18 to 75 years old (including the boundary value);
- •Patients with locally advanced or metastatic pancreatic cancer confirmed by histology or cytology. Patients with locally advanced or metastatic pancreatic cancer that cannot be surgically resected and have failed standard first - or second-line treatments, or have intolerable toxic and side effects of the existing standard treatments, or are not applicable to standard treatments at the present stage, or refuse standard treatments;
- •According to RECIST version 1.1, there is at least one evaluable tumor lesion;
- •The toxic reactions caused by previous anti-tumor treatment were relieved to grade 0-1 (according to NCI CTCAE version 5.0) or to an acceptable level of the inclusion/exclusion criteria. Except for other toxicities such as hair loss and vitiligo that researchers consider not to pose a safety risk to the subjects;
- •Have sufficient organ functions;
- •The physical condition score of the Eastern Cooperative Oncology Group (ECOG) in the United States was 0-1;
- •The expected survival period is more than 3 months;
- •Premenopausal female subjects had negative blood pregnancy results before the start of the study treatment and were willing to abstain from sex or take medically recognized effective contraceptive measures (such as intrauterine devices, condoms) within 6 months from the signing of the informed consent form until the end of the last infusion;
- •Male subjects are willing to abstain from sexual activity or take medically recognized effective contraceptive measures for 6 months from the date of signing the informed consent form until the end of the last infusion, and not donate sperm during this period.
排除标准
- •Participate in clinical trials of other drugs within 30 days before the first infusion;
- •Within 30 days before the first infusion, there is a history of allogeneic or autologous T cell, NK cell and other cell therapy;
- •Allergic to any component of iNKT cell injection;
- •The following treatments or drugs were received before the first infusion:The use of systemic corticosteroids or immunosuppressive drugs within 14 days before the start of the study treatment, excluding local, intranasal, intraocular, intra-articular or inhaled corticosteroids, or receiving systemic steroid hormone replacement therapy at a dose equivalent to 10mg/d prednisone, Short-term (≤7 days) use of corticosteroids is permitted for prevention (such as allergy to contrast agents) or treatment of non-autoimmune conditions (such as delay-type hypersensitivity reactions caused by exposure to allergens); The attenuated live vaccine was administered within 30 days before the start of the research treatment;
- •Brain metastasis or the presence of spinal cord compression;
- •The subject is diagnosed with severe autoimmune diseases that require systemic immunosuppressants (including but not limited to: steroids) for treatment, or immune-mediated symptomatic diseases, including ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE), and autoimmune vasculitis (e.g., Wegener's granulomatosis);
- •Within 5 years prior to the first infusion, there have been other active malignant tumors, except for those malignant tumors that can be treated locally and have been cured (such as basal cell or squamous cell carcinoma of the skin, superficial or non-invasive bladder cancer, carcinoma in situ of the cervix, intraductal carcinoma in situ of the breast, papillary thyroid carcinoma);
- •Within 6 months before the first infusion, the following situations occur: transient ischemic attack, cerebrovascular accident, myocardial infarction, unstable angina pectoris; Congestive heart failure classified as grade III or IV by the New York Heart Association (NYHA); Left ventricular ejection fraction < 50%; Or severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, II-III atrioventricular block, etc. Or use a cardiac pacemaker; The electrocardiogram results show clinically significant abnormalities, or QTcF≥450ms (if the first examination is abnormal, retests can be conducted at least 5 minutes later, and the comprehensive result/average value can be taken to determine the qualification);
- •There is a history of interstitial lung disease requiring hormone therapy in the past, or there is currently interstitial lung disease;
- •There is effusion in the thoracic cavity, pericardium and peritoneal cavity;
- •Within two weeks before the first infusion, there were active bacterial, viral, fungal infections, etc;
- •Within 2 weeks before the first infusion, there were uncontrolled concurrent diseases including but not limited to: uncontrolled hypertension (systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥100mmHg) or poorly controlled diabetes even with standardized treatment;
- •Subjects with esophageal or gastric varices that require immediate intervention, intestinal obstruction, or those who, based on the researcher's opinion or after consultation with gastroenterologists or hepatologists, are considered to have a higher risk of bleeding, have evidence of portal hypertension (including splenomegaly found through imaging examinations), or have a previous history of varicose vein bleeding;
- •Suffering from active infections, including positive hepatitis B surface antigen [HBsAg] and HBV-DNA > the lower limit of the research center's detection value, positive hepatitis C antibody [HCV-Ab] and HCV-RNA > the lower limit of the research center's detection value; Human immunodeficiency virus (HIV) infection or known positive antibodies for acquired immunodeficiency syndrome (AIDS) and syphilis;
- •Combined with severe mental illness, or having a clear history of neurological or mental disorders (such as epilepsy, dementia, schizophrenia, etc.), or having a known history of alcohol abuse, abuse of psychotropic drugs or drug abuse;
- •During the screening period or before the start of the research treatment, a fever of unknown cause >38.0°C occurred (except for the fever caused by the tumor as judged by the researcher);
- •There is a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
- •Women who are pregnant or breastfeeding;
- •As judged by the researcher, the underlying condition of the subjects may increase their risk of receiving the studied drug treatment, or cause confusion in the interpretation of the toxic reactions and AE that occur;
- •Other circumstances where the researcher deems it inappropriate to participate in this study.
研究组 & 干预措施
iNKT
Experimental
干预措施: iNKT (Drug)
结局指标
主要结局
Dose-limiting toxicity (DLT)
时间窗: After 28 days of infusion
Safety
Maximum tolerated dose (MTD)
时间窗: After 28 days of infusion
tolerability
次要结局
- Antitumor efficacy-Disease control rate (DCR)(About 2 years)
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0(About 2 years)
- Antitumor efficacy-Objective response rate (ORR)(About 2 years)
- Antitumor efficacy-Duration of response (DOR)(About 2 years)
- Antitumor efficacy-Progression-free survival (PFS)(About 2 years)
- Antitumor efficacy-Overall survival (OS)(About 2 years)
研究者
Jiang Long
Chief physician of hepatobiliary and pancreatic surgery
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
相似试验
招募中
不适用
Clinical Study on the Treatment of Type 1 Diabetes With CNK-UT009 Cell InjectionType 1 Diabetes (T1D)NCT07051564Zibo Central Hospital12
尚未招募
1 期
A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After TransplantationAcute Myeloid LeukemiaNCT06441084Nuwacell Biotechnologies Co., Ltd.15
已完成
1 期
Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell TransplantationHematological MalignancyNCT01853358Institut Paoli-Calmettes17
撤回
1 期
CD56+CD3- NK Cells Following Allogeneic Stem Cell TransplantationHaematological MalignanciesAllogeneic Stem Cell TransplantCD56+CD3- NK CellsNCT01336478Imperial College London
撤回
早期 1 期
An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor PatientsSolid Tumors (Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Cholangiocarcinoma, Lung Cancer and Ovarian Cancer)NCT06284226Beijing Kejing Biotechnology Co., Ltd.